0
Login
Home Credit Perspective Reports Bliss GVS Pharma Limited
bg-rating-rationales

Entity-Specific Rating Rationales

08 Apr 2026

Bliss GVS Pharma Limited: [ICRA]A-(Stable)/[ICRA] A2+; assigned

Bliss GVS Pharma Limited: [ICRA]A-(Stable)/[ICRA] A2+; assigned

icon-download
bg-rating-crediet-reports

Entity-Specific Credit Perspective Reports

30 Apr 2026

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited (Non-SF)

Ratings

Description
Short Term
Medium Term
Long Term
Issuer
Long-term/Short-term – Fund-based/Non-fund based – Others [ICRA]A2+ -- [ICRA]A-(Stable) --

Our Analysts

Analyst 1

Aman Mundhada

Analyst 2

Mythri Macherla

Sector Head

Jitin Makkar
bg-rating-research

Most Trending Research Reports

icon-prime

icon-download icon-download icon-sbscribe icon-sbscribe

View More
bg-rating-rationales

Rating Rationales
icon-download

View More

Beyond renewables - Investment outlook and emerging role of thermal power

Girishkumar Kadam,Ankit Jain,Asmita Pant

07 May 2026 04:00 PM
Register now 7 days Left

West Asia Crisis-Impact and Outlook on Oil & Gas and downstream sectors

Girishkumar Kadam,Prashant Vasisht

29 Apr 2026 04:00 PM

Banking Outlook: Growth and Profitability in an Uncertain Geopolitical Environment

Karthik Srinivasan,Anil Gupta,Sachin Sachdeva

22 Apr 2026 04:00 PM

PPT Icon PPT
View all

Podcast


New CPI and GDP Series | FY27 Growth and Inflation Outlook | ICRA Insight by Aditi Nayar

Mar 2026

View More

Media Release



View More
Ask Our Industry Analyst Get in touch with our Business Representative
Please enter your name
Please enter your mobile number
Please enter your email id
Please enter your company name
Name should not be greater than 50 characters
Please choose sector
Please enter your query
Query to have atleast ten characters
Query should not be greater than 1,000 characters
Please verify you are not a Robot.